Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -72.50% is 93% below its 5-year average of -37.52%, near the low end of its 5-year range (-72.50%–-24.36%).
57.73% below its 12-month average of -45.97%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -20.94%.
RETURN ON ASSETS (ROA)
-72.50%
RETURN ON ASSETS (ROA) AVG TTM
-45.97%
RETURN ON ASSETS (ROA) AVG 3Y
-37.50%
RETURN ON ASSETS (ROA) AVG 5Y
-37.52%
RETURN ON ASSETS (ROA) AVG 10Y
-41.17%
RETURN ON ASSETS (ROA) AVG 15Y
-36.21%
RETURN ON ASSETS (ROA) AVG 20Y
-40.91%
CURRENT VS TTM AVG
-57.73%
CURRENT VS 3Y AVG
-93.31%
CURRENT VS 5Y AVG
-93.21%
CURRENT VS 10Y AVG
-76.11%
CURRENT VS 15Y AVG
-100.21%
CURRENT VS 20Y AVG
-77.24%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-124.88%
vs the sector median at left
Savara Inc.
Market Cap
$959.06M
Return on Assets (ROA)
-72.50%
TTM Avg
-45.97%
3Y Avg
-37.50%
5Y Avg
-37.52%
Market Cap
$952.79M
Return on Assets (ROA)
-13.12%
TTM Avg
-18.77%
3Y Avg
-18.48%
5Y Avg
-18.48%
Market Cap
$970.71M
Return on Assets (ROA)
1.18%
TTM Avg
-2.92%
3Y Avg
-0.56%
5Y Avg
1.87%
Market Cap
$977.08M
Return on Assets (ROA)
19.92%
TTM Avg
-50.75%
3Y Avg
-41.99%
5Y Avg
-34.79%
Market Cap
$943.21M
Return on Assets (ROA)
-30.07%
TTM Avg
-30.07%
3Y Avg
-30.07%
5Y Avg
-30.07%
Market Cap
$980.55M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$980.66M
Return on Assets (ROA)
-23.69%
TTM Avg
-98.11%
3Y Avg
-69.18%
5Y Avg
-69.18%
Market Cap
$926.80M
Return on Assets (ROA)
-50.49%
TTM Avg
-30.32%
3Y Avg
-31.10%
5Y Avg
-27.11%
Market Cap
$991.24M
Return on Assets (ROA)
-22.90%
TTM Avg
-17.96%
3Y Avg
-22.57%
5Y Avg
-25.02%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Savara Inc. (SVRA) | $959.06M | -72.50% | -45.97% | -37.50% | -37.52% |
| Aktis Oncology, Inc. (AKTS)vs › | $952.79M | -13.12% | -18.77% | -18.48% | -18.48% |
| Pacira BioSciences, Inc. (PCRX)vs › | $970.71M | 1.18% | -2.92% | -0.56% | 1.87% |
| MeiraGTx Holdings plc (MGTX)vs › | $977.08M | 19.92% | -50.75% | -41.99% | -34.79% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $943.21M | -30.07% | -30.07% | -30.07% | -30.07% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $980.55M | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $980.66M | -23.69% | -98.11% | -69.18% | -69.18% |
| Kura Oncology, Inc. (KURA)vs › | $926.80M | -50.49% | -30.32% | -31.10% | -27.11% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $991.24M | -22.90% | -17.96% | -22.57% | -25.02% |
| MoonLake Immunotherapeutics (MLTX)vs › | $923.17M | -45.94% | -39.23% | -37.58% | -117.41% |
ROA
-72.5%
ROE
-97.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -46.89% |
| 2024-12-31 | -45.04% |
| 2023-12-31 | -30.80% |
| 2022-12-31 | -27.29% |
| 2021-12-31 | -24.36% |
| 2020-12-31 | -50.76% |
| 2019-12-31 | -57.39% |
| 2018-12-31 | -40.39% |
| 2017-12-31 | -18.67% |
| 2016-12-31 | -37.75% |
| 2015-12-31 | -73.49% |
| 2014-12-31 | -40.71% |
| 2013-12-31 | -38.88% |
| 2012-12-31 | -33.13% |
| 2011-12-31 | -21.44% |
| 2010-12-31 | -29.67% |
| 2009-12-31 | -125.45% |
| 2008-12-31 | -248.83% |
| 2007-12-31 | -64.10% |
| 2006-12-31 | -55.55% |
| 2005-12-31 | -104.91% |
| 2004-12-31 | -49.24% |
| 2003-12-31 | -54.45% |
| 2002-12-31 | -1615.50% |
| 2001-12-31 | -5877.25% |
| 2000-12-31 | -24.87% |
